Lots of interesting abstracts and cases were submitted for TCTAP 2026. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge!
ABS20251114_0004
Comprehensive Outcomes of Early TAVR Versus Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: Evidence From the EARLY TAVR Trial and Sub-Analysis
By Philippe Généreux, Brian Lindman , Allan Schwartz, Martin Leon
Presenter
Philippe Généreux
Authors
Philippe Généreux1, Brian Lindman 2, Allan Schwartz3, Martin Leon4
Affiliation
Morristown Medical Center, USA1, Vanderbilt University Medical Center, USA2, Columbia University Medical Center, USA3, Cardiovascular Research Foundation, USA4
View Study Report
ABS20251114_0004
Minimalist TAVR
Comprehensive Outcomes of Early TAVR Versus Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: Evidence From the EARLY TAVR Trial and Sub-Analysis
Philippe Généreux1, Brian Lindman 2, Allan Schwartz3, Martin Leon4
Morristown Medical Center, USA1, Vanderbilt University Medical Center, USA2, Columbia University Medical Center, USA3, Cardiovascular Research Foundation, USA4
Background
The EARLY TAVR trial demonstrated a strategy of early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) for the primary endpoint in patients with asymptomatic severe aortic stenosis (AS). Since the primary endpoint publication, 7 sub-analyses, including those on biomarkers, left-ventricular health, and cardiac damage, have been reported. A comprehensive overview of these findings has not yet been presented.
Methods
EARLY TAVR is a prospective, multicenter, randomized, controlled trial in which transfemoral TAVR with the balloon-expandable SAPIEN 3 or SAPIEN 3 Ultra valve was compared with guideline-recommended CS among patients with asymptomatic, severe AS. Symptomatic status was assessed by a clinical history and a treadmill stress test or detailed health history alone in patients unable to perform a stress test. Key exclusion criteria included patients aged < 65 years, unsuitable anatomy for transfemoral TAVR, and any Class I indication for aortic valve replacement (AVR). The primary end point was a composite of death, stroke, or unplanned cardiovascular hospitalization.
Results
At 75 centers in the United States and Canada, 901 patients underwent 1:1 randomization, with 455 assigned to TAVR and 446 to CS. The mean age was 76 years, 69% were male, and the mean Society of Thoracic Surgeons score was 1.8%. A primary endpoint event occurred in 122 patients (26.8%) in the TAVR group and in 202 patients (45.3%) in the CS group (hazard ratio, 0.50; 95% confidence interval, 0.40 to 0.63; P<0.001). Death occurred in 8.4% of patients assigned to TAVR and 9.2% of patients assigned to CS, stroke occurred in 4.2% and 6.7%, respectively, and unplanned cardiovascular hospitalization occurred in 20.9% and 41.7%. Through a median follow-up of 3.8 years, 87.0% of CS patients underwent delayed AVR.
Conclusion
In patients with asymptomatic severe AS, early TAVR demonstrated improved clinical outcomes in multiple patient subgroups. A synthesized review of these data will be available at the time of the presentation.